Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.
The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30 include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.
Market Dynamics
Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.
Key features of the study:
- This report provides in-depth analysis of the market, tuberculosis drugs market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2019 – 2027), considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tuberculosis drugs market based on the following parameters such as company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include, include Johnson & Johnson Services, LLC, Lupin Ltd, Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., and others.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to product launches, governmental initiatives, market expansion, and marketing tactics
- The global tuberculosis drugs market report caters to various stakeholders in this industry such as investors, product manufacturers, distributors, and suppliers of TB drugs, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Tuberculosis Drugs Market, by Therapy Type :
- First Line Therapy
- Isoniazid (INH)
- rifampicin (RIF)
- Ethambutol (EMB)
- Pyrazinamide (PZA)
- Streptomycin (SM).
- Second Line Therapy
- Fluoroquinolones
- Injectable antituberculosis drugs
- Global Tuberculosis Drugs Market, by Disease Type:
- Global Tuberculosis Drugs Market, by Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Tuberculosis Drugs Market, by Region:
- North America
- By Country:
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Therapy Type:
- First Line Therapy
- Second Line Therapy
- By Disease Type:
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Lupin ltd*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Johnson & Johnson Services, LLC
- Novartis AG
- Macleods Pharmaceuticals Ltd.
- Otsuka Pharmaceutical Co., Ltd
- Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.
